X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1940) 1940
Publication (187) 187
Book Review (39) 39
Newsletter (33) 33
Book Chapter (21) 21
Conference Proceeding (7) 7
Newspaper Article (4) 4
Reference (2) 2
Paper (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1096) 1096
index medicus (999) 999
animals (931) 931
thiazolidinediones (892) 892
thiazolidinediones - pharmacology (662) 662
male (651) 651
thiazolidinediones - therapeutic use (475) 475
rosiglitazone (456) 456
female (451) 451
pharmacology & pharmacy (439) 439
rats (421) 421
mice (417) 417
hypoglycemic agents - therapeutic use (400) 400
pioglitazone (361) 361
diabetes mellitus, type 2 - drug therapy (346) 346
hypoglycemic agents - pharmacology (345) 345
ppar-gamma (338) 338
diabetes (327) 327
troglitazone (322) 322
ppar gamma - agonists (305) 305
insulin resistance (292) 292
endocrinology & metabolism (282) 282
type 2 diabetes (280) 280
ppar gamma - metabolism (228) 228
insulin-resistance (217) 217
middle aged (217) 217
hypoglycemic agents - adverse effects (214) 214
thiazolidinediones - adverse effects (210) 210
insulin (200) 200
glucose (190) 190
thiazolidinedione (189) 189
dose-response relationship, drug (186) 186
toxicology (182) 182
expression (179) 179
thiazolidinediones - administration & dosage (179) 179
activated receptor-gamma (176) 176
apoptosis (170) 170
biochemistry & molecular biology (169) 169
metformin (169) 169
activated-receptor-gamma (166) 166
adult (160) 160
hypoglycemic agents (157) 157
in-vitro (157) 157
ligands (152) 152
oxidative stress (152) 152
aged (150) 150
cells, cultured (148) 148
research (148) 148
disease models, animal (142) 142
rats, wistar (142) 142
drug therapy (138) 138
inflammation (136) 136
chemistry, medicinal (133) 133
cell line, tumor (132) 132
analysis (130) 130
thiazolidinediones - toxicity (128) 128
cancer (126) 126
blood glucose - metabolism (125) 125
metabolism (125) 125
gene-expression (124) 124
chromans - pharmacology (123) 123
mice, inbred c57bl (121) 121
apoptosis - drug effects (118) 118
diabetes mellitus (118) 118
type-2 diabetes-mellitus (118) 118
rats, sprague-dawley (116) 116
drug therapy, combination (114) 114
physiological aspects (112) 112
pparγ (112) 112
liver - drug effects (111) 111
ppar gamma (110) 110
care and treatment (109) 109
cell biology (109) 109
oncology (109) 109
drugs (108) 108
hypoglycemic agents - administration & dosage (108) 108
liver (108) 108
medicine & public health (108) 108
thiazolidinediones - chemistry (108) 108
risk factors (107) 107
metformin - therapeutic use (105) 105
article (104) 104
obesity (104) 104
cell line (101) 101
treatment outcome (99) 99
dextrose (98) 98
thiazoles - pharmacology (97) 97
thiazoles - therapeutic use (96) 96
cell survival - drug effects (94) 94
health aspects (93) 93
neurosciences (93) 93
therapy (93) 93
hypoglycemic agents - toxicity (91) 91
internal medicine (90) 90
glycemic control (89) 89
risk (89) 89
ppar gamma - genetics (88) 88
time factors (88) 88
gene expression (86) 86
toxicity (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1977) 1977
Japanese (6) 6
Chinese (4) 4
German (4) 4
French (3) 3
Spanish (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicology, ISSN 0300-483X, 2005, Volume 216, Issue 2, pp. 154 - 167
Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites. In order to reduce attrition due... 
Reactive metabolites | Cytotoxicity | Metabolism-mediated toxicity | CYP3A4 | In vitro screening | Adverse drug reactions (ADRs) | CYTOCHROME-P450 | MEDIATED CYTOTOXICITY | HUMAN HEPATOCYTE CULTURES | in vitro screening | CARBAMAZEPINE | adverse drug reactions (ADRs) | STABLE EXPRESSION | INDUCTION | metabolism-mediated toxicity | IDIOSYNCRATIC DRUG-REACTIONS | CHINESE-HAMSTER CELLS | HEPG2 CELLS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | reactive metabolites | HUMAN-LIVER-MICROSOMES | cytotoxicity | Microsomes - metabolism | Thiazoles - metabolism | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 CYP3A | Coculture Techniques | Humans | Thiazolidinediones - toxicity | Cytochrome P-450 Enzyme System - metabolism | Isoniazid - toxicity | Xenobiotics - toxicity | Chromans - metabolism | Flutamide - metabolism | Triazolam - toxicity | Microsomes - drug effects | Triazolam - metabolism | Adenosine Triphosphate - metabolism | Carbamazepine - toxicity | Toxicity Tests - methods | Xenobiotics - metabolism | Cell Culture Techniques | Cell Survival - drug effects | Albendazole - toxicity | Tamoxifen - toxicity | Dapsone - metabolism | Dapsone - toxicity | Cell Line, Tumor | Glutathione - chemistry | Troglitazone | Buthionine Sulfoximine - pharmacology | Quinidine - toxicity | Amitriptyline - toxicity | Glutathione - metabolism | Flutamide - toxicity | Substrate Specificity | Piperazines - metabolism | Piperazines - toxicity | Ochratoxins - metabolism | Xenobiotics - chemistry | Tetrazolium Salts - metabolism | Carbamazepine - metabolism | Quinidine - metabolism | Tamoxifen - metabolism | Amitriptyline - metabolism | Glutathione - antagonists & inhibitors | Enzyme Activation - drug effects | Thiazolidinediones - metabolism | Ochratoxins - toxicity | Thiazoles - toxicity | Animals | Albendazole - metabolism | Chromans - toxicity | Isoniazid - metabolism | Phosphates | Metabolites | Ketoconazole | Cytochrome P-450 | Control systems | Xenobiotics | Glutathione
Journal Article
Journal Article
Journal Article
Toxicology in Vitro, ISSN 0887-2333, 12/2015, Volume 30, Issue 1, pp. 79 - 94
Journal Article
Journal of Diabetes, ISSN 1753-0393, 11/2015, Volume 7, Issue 6, pp. 839 - 849
Journal Article
Chemical Research in Toxicology, ISSN 0893-228X, 09/2012, Volume 25, Issue 9, pp. 1938 - 1947
Journal Article
Journal Article
Journal of Cerebral Blood Flow & Metabolism, ISSN 0271-678X, 4/2014, Volume 34, Issue 4, pp. 646 - 653
The strategies to protect against the disrupted blood–brain barrier (BBB) in HIV-1 infection are not well developed. Therefore, we investigated the potential... 
Tat protein | Neurotoxicity | Matrix metalloproteinase | Blood-brain barrier | Peroxisome proliferator-activated receptor | Human immunodeficiency virus-1 | ACTIVATION | MATRIX-METALLOPROTEINASE | TRANSENDOTHELIAL MIGRATION | HUMAN-IMMUNODEFICIENCY-VIRUS | CEREBROSPINAL-FLUID | NEUROSCIENCES | blood brain barrier | human immunodeficiency virus-1 | neurotoxicity | POLYMERASE-CHAIN-REACTION | ENDOCRINOLOGY & METABOLISM | matrix metalloproteinase | CENTRAL-NERVOUS-SYSTEM | INFECTION | peroxisome proliferator-activated receptor | HEMATOLOGY | EXPRESSION | BRAIN ENDOTHELIAL-CELLS | Neurons - pathology | Cell Count | Astrocytes - pathology | Capillary Permeability - drug effects | Male | Fenofibrate - therapeutic use | Fenofibrate - pharmacology | Thiazolidinediones - therapeutic use | Neurotoxicity Syndromes - pathology | Matrix Metalloproteinase 9 - genetics | Neurons - drug effects | Thiazolidinediones - pharmacology | tat Gene Products, Human Immunodeficiency Virus - toxicity | Tight Junction Proteins - metabolism | Peroxisome Proliferator-Activated Receptors - agonists | Astrocytes - drug effects | Neurotoxicity Syndromes - prevention & control | Matrix Metalloproteinase 9 - deficiency | Blood-Brain Barrier - drug effects | Blood-Brain Barrier - metabolism | Mice, Knockout | Blood-Brain Barrier - pathology | Animals | Neurotoxicity Syndromes - metabolism | Mice | Index Medicus | blood–brain barrier | Original
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 12/2012, Volume 697, Issue 1-3, pp. 13 - 23
Thiazolidinediones have been established as a drug class of significant importance in the treatment of Type II diabetes mellitus and have more recently... 
Oxidative stress | Anti-diabetic | Pyrrolidinedione | Anti-cancer | Thiazolidinedione | PPARγ | PPAR | CELLS | LIPOSARCOMA | TROGLITAZONE | METABOLIC-ACTIVATION | PPAR gamma | IN-VITRO | HEPATOCELLULAR-CARCINOMA | GROWTH | ACTIVATED-RECEPTOR-GAMMA | PHARMACOLOGY & PHARMACY | HEPATOTOXICITY | DIFFERENTIATION | Succinimides - metabolism | Phosphorylation | Glutathione - metabolism | Hypoglycemic Agents - metabolism | Humans | Microsomes, Liver - metabolism | Caspase 3 - metabolism | Thiazolidinediones - toxicity | Structure-Activity Relationship | Fatty Acid-Binding Proteins - metabolism | Thiazolidinediones - chemistry | PPAR gamma - metabolism | Protein Carbonylation - drug effects | Succinimides - chemistry | Antineoplastic Agents - toxicity | Antineoplastic Agents - metabolism | Dose-Response Relationship, Drug | Hypoglycemic Agents - toxicity | Microsomes, Liver - drug effects | Biotransformation | Drug Design | Liver Neoplasms - pathology | Molecular Structure | Succinimides - toxicity | Cell Survival - drug effects | Gene Expression Regulation | Hypoglycemic Agents - chemistry | 3T3-L1 Cells | Antineoplastic Agents - chemistry | Receptor Protein-Tyrosine Kinases - drug effects | Receptor Protein-Tyrosine Kinases - metabolism | Fatty Acid-Binding Proteins - genetics | Thiazolidinediones - metabolism | Animals | Liver Neoplasms - metabolism | PPAR gamma - agonists | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Chromans - toxicity | Receptors, Peptide - metabolism | Liver cancer | Care and treatment | Metabolites | Diabetes | Gene expression | Thiazolidinediones | Cancer | Index Medicus | Drugs | thiazolidinediones | Tumor markers | Toxicity | Diabetes mellitus | Cytotoxicity | troglitazone | Tumor cell lines | Drug development | pioglitazone | Hepatocytes | AP2 gene | Development | rosiglitazone
Journal Article